ARQT Arcutis Biotherapeutics, Inc.
Q3 2025 10-Q
Arcutis Biotherapeutics, Inc. (ARQT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New regulatory risk from One Big Beautiful Bill Act (Jul 2025) cutting Medicaid spending by $1 trillion, potentially lowering life sciences revenue
- • Most material update: tax law changes including possible increased U.S. tax expense and one-time charges affecting deferred tax asset values
Quarterly Financial SummaryXBRL
Revenue
$99M
Net Income
$7M
Operating Margin
8.6%
Net Margin
7.5%
ROE
4.7%
Total Assets
$371M
Source: XBRL data from Arcutis Biotherapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Arcutis Biotherapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.